First Light Biosciences is a development stage company developing novel medical diagnostic products for preventing and detecting healthcare associated infections. The company’s MultiPath technology, which uses digital imaging to count cells and molecules without magnification, enables sensitivity comparable to genetic diagnostics but with improved cost-effectiveness, ease-of-use, and automation. The company aims to be the first to enable any hospital to afford to use rapid screening to prevent hospital infections caused by bacterial agents such as MRSA. The company’s products can be used to detect a broad range of infectious disease targets, including antibiotic resistant bacteria, toxins, viruses, and biomarkers. Automation of sophisticated diagnostics expands the use of the most advanced techniques throughout the scope of health care facilities, from large laboratories to small doctor’s offices, thereby ensuring that all patients receive the best care possible.